1-7 of 7
Myrthe J. van Dijk
Close
Sort by
Journal Articles

Roxyscan: A Novel Method to Assess Red Blood Cell Resilience to Oxidative Stress in Sickle Cell Disease

Carolina A. Hernandez, Marissa J.M. Traets, Myrthe J. van Dijk, Wouter W. van Solinge, Frans A. Kuypers, Minke A.E. Rab, Eduard J. Van Beers, Richard van Wijk
Journal: Blood
Blood (2023) 142 (Supplement 1): 2497.
https://doi.org/10.1182/blood-2023-188676
Published: 2023
Journal Articles

One-Year Safety and Efficacy of Mitapivat in Sickle Cell Disease: Follow-up Results of a Phase 2, Open-Label Study

Myrthe J. van Dijk, Minke A.E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Cleo Derichs, Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith J.M. Jans, Wouter W. van Solinge, Roger E.G. Schutgens, Richard van Wijk, Eduard J. Van Beers
Journal: Blood
Blood (2023) 142 (Supplement 1): 2515.
https://doi.org/10.1182/blood-2023-172829
Published: 2023
Journal Articles

Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat

Myrthe J. van Dijk, Sigrid van der Veen, Minke A.E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Cleo Derichs, Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith J.M. Jans, Richard van Wijk, Eduard J. van Beers
Journal: Blood
Blood (2022) 140 (Supplement 1): 21–23.
https://doi.org/10.1182/blood-2022-155997
Published: 2022
Journal Articles

An Endogenous Metabolic Modulator Composition Improves Hydration Status and Decreases Adhesion Properties of Red Blood Cells from Patients with Sickle Cell Disease

Myrthe J. van Dijk, Marissa J.M. Traets, Brigitte A. van Oirschot, Jonathan R.A. de Wilde, Jennifer Bos, Wouter W. van Solinge, Margaret J. Koziel, Revati Wani, Eduard J. van Beers, Richard van Wijk, Minke A.E. Rab
Journal: Blood
Blood (2022) 140 (Supplement 1): 8235–8237.
https://doi.org/10.1182/blood-2022-166177
Published: 2022
Journal Articles

Movement Behavior in Adults with Sickle Cell Disease Compared to Healthy Adults: Preliminary Results

Aaron Heeren, Charlotte F.J. Van Tuijn, Myrthe J. van Dijk, Eduard J. van Beers, Bart J. Biemond, Erfan Nur, Merel Timmer
Journal: Blood
Blood (2022) 140 (Supplement 1): 2558–2559.
https://doi.org/10.1182/blood-2022-163254
Published: 2022
Journal Articles

Safety and Efficacy of Mitapivat (AG-348), an Oral Activator of Pyruvate Kinase R, in Subjects with Sickle Cell Disease: A Phase 2, Open-Label Study (ESTIMATE)

Myrthe J. van Dijk, Minke A.E. Rab, Anita W. Rijneveld, Erfan Nur, Marije Bartels, Judith J.M. Jans, Wouter W. van Solinge, Roger E.G. Schutgens, Richard van Wijk, Eduard J. Van Beers
Journal: Blood
Blood (2021) 138 (Supplement 1): 2047.
https://doi.org/10.1182/blood-2021-150234
Published: 2021
Journal Articles

Pharmacodynamic Effects of AG-946, a Highly Potent Next-Generation Activator of Pyruvate Kinase, in Ex Vivo Treatment of Red Blood Cells from Sickle Cell Disease Patients

Minke A.E. Rab, Myrthe J. Van Dijk, Jennifer Bos, Brigitte A. van Oirschot, Johan Gerrits, Penelope A. Kosinski, Charles Kung, Judith J.M. Jans, Eduard J. Van Beers, Lenny Dang, Richard van Wijk
Journal: Blood
Blood (2021) 138 (Supplement 1): 2029.
https://doi.org/10.1182/blood-2021-145374
Published: 2021